158669-26-2

Usage

Uses

Used in Pharmaceutical Industry:
4-Iodo-2-methoxypyridine-3-carboxaldehyde is used as a key intermediate in the synthesis of insulin-like growth factor 1-receptor (IGF-1R) inhibitors. These inhibitors are designed to target and block the activity of IGF-1R, which plays a crucial role in cell growth, proliferation, and survival. By inhibiting IGF-1R, these compounds can effectively suppress tumor growth and display anti-tumor activity, making them valuable in the development of cancer therapeutics.
In addition to its role in the synthesis of IGF-1R inhibitors, 4-Iodo-2-methoxypyridine-3-carboxaldehyde may also find applications in other areas of the pharmaceutical industry, such as the development of novel drugs targeting different receptors or enzymes involved in various diseases. Its unique chemical structure allows for further functionalization and modification, enabling the creation of new compounds with potential therapeutic benefits.

InChI:InChI=1/C7H6INO2/c1-11-7-5(4-10)6(8)2-3-9-7/h2-4H,1H3

Upstream product

• 1628-89-3 2-methoxypyridine 
• 105669-53-2 N-formyl-N,N',N'-trimethylethylenediamine 
• 124-41-4 sodium methylate 
• 113975-22-7 2-fluoro-3-iodopyridine 
• 109-94-4 formic acid ethyl ester 
• 22282-70-8 2-fluoro-4-iodopyridine 
• 1634-04-4 tert-butyl methyl ether 
• 916851-24-6 N-ethoxyethyl-N-methylformamide 

Downstream Products

• 726206-53-7 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde 

Relevant academic research and scientific papers

Catalytic enantioselective synthesis of 20(S)-camptothecin: A practical application of the sharpless asymmetric dihydroxylation reaction

The first catalytic asymmetric route to 20(S)-camptothecin was achieved, using as the key steps a tandem intramolecular Heck reaction/olefin isomerization process and a Sharpless asymmetric dihydroxylation (AD) reaction.

INHIBITORS OF BETA SECRETASE

The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) (I) and (II) wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes and other metabolic disorders.

INHIBITORS OF BETA SECRETASE

The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) (I) and (II) and the tautomers and the stereoisomeric forms thereof, wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes and other metabolic disorders.

PYRROLO PYRIMIDINE DERIVATIVE

The compound represented by general formula (I) has strong Axl inhibition activity by means of a pyridone ring structure being introduced into a pyrrolo pyrimidine skeleton, and so the result can serve as a treatment agent for Axl-related diseases, for example cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors, renal disease, immune system disorders, and cardiovascular disease.

PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Formula (I). Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.

PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufact

PYRIDINONE COMPOUNDS

The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: and is further directed to pharmaceutical compositions comprising the compound; and methods for treating proliferative diseases, such as ca

PROCESS FOR PRODUCING TRICYCLIC KETONE

In order to efficiently supply CPT, which is a starting compound of irinotecan hydrochloride and a variety of camptothecin derivatives, by a practical total synthesis, the invention provides a means of efficiently preparing a tricyclic ketone that corresp

Imidazole based kinase inhibitors

The present invention provides compounds having Formula I and their use for the treatment of cancer.

Novel tyrosine kinase inhibitors

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.